elloramycin: isolated from Streptomyces olivaceus; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
elloramycin A : A member of the class of tetracenomycins that is 8-demethyltetracenomycin C in which the hydroxyl hydrogens at position 8 and 10 a are replaced by a 2,3,4-tri-O-methyl-alpha-L-rhamnosyl and methyl groups respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 10009567 |
| CHEMBL ID | 1957887 |
| CHEBI ID | 78288 |
| MeSH ID | M0136754 |
| Synonym |
|---|
| C12381 , |
| elloramycin a |
| 97218-42-3 |
| elloramycin |
| chebi:78288 , |
| CHEMBL1957887 , |
| methyl (6ar,7s,10ar)-3-[(6-deoxy-2,3,4-tri-o-methyl-alpha-l-mannopyranosyl)oxy]-6a,7,12-trihydroxy-8,10a-dimethoxy-1-methyl-6,10,11-trioxo-6,6a,7,10,10a,11-hexahydrotetracene-2-carboxylate |
| methyl (6ar,7s,10ar)-6a,7,12-trihydroxy-8,10a-dimethoxy-1-methyl-6,10,11-trioxo-3-[(2s,3r,4r,5s,6s)-3,4,5-trimethoxy-6-methyl-tetrahydropyran-2-yl]oxy-7h-tetracene-2-carboxylate |
| methyl (6ar,7s,10ar)-6a,7,12-trihydroxy-8,10a-dimethoxy-1-methyl-6,10,11-trioxo-3-[(2s,3r,4r,5s,6s)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy-7h-tetracene-2-carboxylate |
| methyl 3-[(6-deoxy-2,3,4-tri-o-methylhexopyranosyl)oxy]-6a,7,12-trihydroxy-8,10a-dimethoxy-1-methyl-6,10,11-trioxo-6,6a,7,10,10a,11-hexahydrotetracene-2-carboxylate |
| DTXSID60914053 |
| Q27105081 |
| Role | Description |
|---|---|
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| alpha-L-rhamnoside | |
| carboxylic ester | An ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl. |
| enol ether | Ethers ROR' where R has a double bond adjacent to the oxygen of the ether linkage. |
| enone | An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. |
| monosaccharide derivative | A carbohydrate derivative that is formally obtained from a monosaccharide. |
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| tetracenomycin | A polyketide based on a tetracene ring structure. |
| methyl ester | Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. |
| tertiary alpha-hydroxy ketone | An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| elloramycin biosynthesis | 15 | 25 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID649275 | Antimicrobial activity against Streptomyces prasinus at 1 mg/mL by disc diffusion assay | 2012 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6 | Ketoolivosyl-tetracenomycin C: a new ketosugar bearing tetracenomycin reveals new insight into the substrate flexibility of glycosyltransferase ElmGT. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||